文献速递免疫规划卫生政策与健康促进

各国对获准用于受控温度链的乙型肝炎疫苗的兴趣:非洲和西太平洋区域的调查结果

Countries' interest in a hepatitis B vaccine licensed for the controlled temperature chain; survey results from African and Western Pacific regions.
PubMed 文献 · Vaccine · 2017-11-10

为评估对获准用于受控温度链(CTC)的乙型肝炎疫苗的需求,世界卫生组织(WHO)在非洲区域和西太平洋区域国家开展调查。25个国家(44%)回复,72%表示CTC将促进乙型肝炎疫苗出生剂次(hepB-BD)的提供;已引入hepB-BD但覆盖率低的国家尤其感兴趣,且疫苗价格会影响采购决策。

要点

  • 25个国家(44%)回复调查,其中西太平洋区域8/11(73%)、非洲区域17/46(37%)。
  • 回复国家中,非洲区域5国、西太平洋区域全部8国已引入普及性hepB-BD。
  • 72%的回复国家表示CTC将促进hepB-BD的提供,疫苗价格会影响采购决策。

核心结论

  • 回复国家认为获准用于CTC的乙型肝炎疫苗产品有益,但疫苗价格会影响采购决策。
  • 已引入hepB-BD但覆盖率低的国家对CTC尤其感兴趣。

研究设计与样本

  • 世界卫生组织(WHO)在非洲区域和西太平洋区域国家开展调查,评估对获准用于CTC的乙型肝炎疫苗产品的需求。
  • 调查共25个国家(44%)回复,其中西太平洋区域8/11(73%)、非洲区域17/46(37%)。

主要发现

  • 回复国家中,非洲区域5国和西太平洋区域全部8国已引入普及性hepB-BD。
  • 72%的回复国家表示CTC将促进hepB-BD的提供。
  • 提供与未提供hepB-BD的国家之间总体回复未检测到差异,但已引入hepB-BD且覆盖率低的国家对CTC尤其感兴趣。

关键数值与推荐

  • WHO推荐疫苗获准用于「受控温度链」(CTC),要求产品至少耐受40°C持续至少3天的温度偏移。
  • 目前尚无乙型肝炎疫苗获准用于CTC。

局限性

  • 国家缺乏hepB-BD和CTC的经验。
  • 国家所评论的是尚未上市的产品。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic hepatitis B infection can be prevented by hepatitis B vaccine birth dose (hepB-BD) given within 24 h after birth, followed by two hepatitis B vaccinations within the first year of life. Yet nearly half of World Health Organization (WHO) Member States do not provide a hepB-BD. Barriers are primarily attributed to vaccine storage and transportation, as well as high rates of home births. Delivering the vaccine outside the cold chain could potentially increase coverage. To do this, WHO recommends vaccines be licensed for use in a "controlled temperature chain" (CTC), which requires a given product to tolerate temperature excursions up to at least 40 °C for a minimum of three days. To date, no hepB vaccine is labelled for CTC. To inform dialogue with manufacturers, WHO conducted a survey among countries in the African and Western Pacific Regions (AFR and WPR) to assess demand for a hepatitis B product licensed for use in a CTC. Twenty-five (44%) countries responded, with 8 of 11 (73%) from the WPR and 17 of 46 (37%) from the AFR. Of these responding countries, 5 in AFR and all 8 in WPR have introduced universal hepB-BD. Seventy-two percent indicated that CTC would facilitate the provision of hepB-BD. While no overall difference in responses was detected between countries either providing or not providing hepB-BD, countries that already introduced hepB-BD but had low hepB-BD coverage were particularly interested in CTC. Irrespective of hepB-BD policy, responding countries suggested that a CTC-licenced product would be beneficial, though the price of such a vaccine would influence procurement decisions. This survey was beneficial to inform the CTC agenda. However, countries' lack of experience with HepB-BD as well as with CTC and the fact that countries were commenting on a product that is not yet on the market should be acknowledged.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Petit D, Tevi-Benissan C, Woodring J, et al. Countries' interest in a hepatitis B vaccine licensed for the controlled temperature chain; survey results from African and Western Pacific regions. Vaccine. 2017. PMID: 29132994. doi:10.1016/j.vaccine.2017.10.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。